NCT03254784View on ClinicalTrials.gov

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

November 4, 2017

Study Completion Date

November 15, 2017

Conditions
Systemic Lupus ErythematosusArthritic PsoriasisPsoriasisInflammatory Bowel Diseases
Interventions
DRUG

BMS-986165 Capsule

Oral capsule

DRUG

BMS-986165 Tablet

Oral tablet

Trial Locations (1)

66219

PRA Health Sciences, Lenexa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03254784 - A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation | Biotech Hunter | Biotech Hunter